Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

Invitation to the Annual General Meeting of Multitude AG

View original at globenewswire.com
“Net result for the period EUR670,694”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Board of Directors proposes approval of the Combined Management Report, the Separate Financial Statements and the Consolidated Financial Statements 2025

    60% confidence
  • Martin Rechtsanwälte GmbH confirmed to the Board of Directors that it possesses the independence required to perform the independent proxy mandate

    60% confidence
  • The company is not aware of any facts that would preclude full discharge of the Board of Directors for the 2025 business year

    60% confidence
  • PricewaterhouseCoopers AG confirmed the Combined Management Report, Separate Financial Statements and Consolidated Financial Statements for 2025 without reservations

    60% confidence
  • The Board of Directors believes that the members standing for re-election collectively ensure that the Board has the competencies required for Multitude's targets, geographical presence and corporate culture

    60% confidence
  • The Board of Directors proposes an ordinary dividend distribution of EUR 0.55 per share, totaling EUR 11,776,677

    60% confidence
  • PricewaterhouseCoopers AG confirmed to the Board of Directors that it possesses the independence required to perform the auditor mandate

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com